Birk Venture invests in BerGenBio. BerGenBio is a privately-held
biotech company built on proprietary screening technology used for
the research and pre-clinical development of novel drug targets and
associated biomarkers. Based on this novel technology the company is
developing first in class therapeutics for the treatment of cancer, with
lead programs against metastatic drug resistant solid tumors, EMT and
drug resistance. Birk Venture is with this engagement delighted to
further participate in new cancer research and treatment.
Birk Venture takes one seat in the board of Directors of the company.
